首页> 美国卫生研究院文献>The British Journal of Ophthalmology >Effect of panretinal photocoagulation on serum levels of laminin in patients with diabetes: a prospective study
【2h】

Effect of panretinal photocoagulation on serum levels of laminin in patients with diabetes: a prospective study

机译:全视网膜光凝对糖尿病患者血清层粘连蛋白水平的影响:一项前瞻性研究

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

BACKGROUND/AIM—Laminin, a major specific non-collagenous glycoprotein of basement membrane, has been proposed as an index of diabetic retinopathy and high serum concentrations have been reported in patients with proliferative diabetic retinopathy. On the other hand, panretinal photocoagulation (PRP) prevents the progression of severe diabetic retinopathy and reverses preretinal neovascularisation. The aim of the study was to investigate the effect of PRP on serum levels of laminin in patients with diabetes.
METHODS—20 patients with diabetes undergoing PRP and 15 patients with mild or moderate non-proliferative diabetic retinopathy in whom a PRP was not performed were included in the study. Serum laminin-P1 (Lam-P1), the largest pepsin resistant fragment of laminin, was determined by radioimmunoassay in each patient before starting PRP and 3 months after it was accomplished. Similarly, a baseline and a 4 month sample were analysed in the non-photocoagulated controls.
RESULTS—Serum Lam-P1 concentrations obtained 3 months after PRP were significantly lower when compared with the initial values (1.62 (SD 0.36) U/ml v 1.91 (0.37) U/ml; p <0.001). A decrease of serum levels of Lam-P1 could be seen in all patients. By contrast, in those patients with mild or moderate non-proliferative diabetic retinopathy in whom a PRP was not performed, no significant changes were detected in serum Lam-P1 concentrations (1.72 (0.20) U/ml v 1.74 (0.17); p=0.250).
CONCLUSION—PRP decreases serum Lam-P1 levels in patients with severe diabetic retinopathy. Thus, the studies addressed to evaluate the usefulness of Lam-P1 as a marker of diabetic retinopathy should consider previous PRP as an influencing factor. Finally, our results suggest that retinal source of Lam-P1 strongly contributes to serum Lam-P1 in patients with severe diabetic retinopathy.

机译:背景/目的—层粘连蛋白是基底膜的主要特异性非胶原糖蛋白,已被提出作为糖尿病性视网膜病的指标,并且已报道了增生性糖尿病性视网膜病患者的血清浓度高。另一方面,全视网膜光凝(PRP)可防止严重的糖尿病性视网膜病变的进展并逆转视网膜前新血管形成。该研究的目的是研究PRP对糖尿病患者血清层粘连蛋白水平的影响。
方法-20例接受PRP的糖尿病患者和15例患有PRP的轻度或中度非增生性糖尿病视网膜病变患者未进行的研究被纳入研究。血清层粘连蛋白-P1(Lam-P1)是层粘连蛋白最大的胃蛋白酶抗性片段,在开始PRP之前和完成后3个月通过放射免疫测定法对每位患者进行了测定。同样,在非光凝对照中分析了基线和4个月的样本。
结果-PRP后3个月获得的血清Lam-P1浓度与初始值相比明显降低(1.62 (SD 0.36)U / ml v 1.91(0.37)U / ml; p <0.001)。所有患者的血清Lam-P1水平均下降。相比之下,在未进行PRP的轻度或中度非增殖性糖尿病性视网膜病患者中,血清Lam-P1浓度未检测到显着变化(1.72(0.20)U / ml v 1.74(0.17); p = 0.250)。
结论—PRP降低了严重糖尿病性视网膜病患者的血清Lam-P1水平。因此,旨在评估Lam-P1作为糖尿病性视网膜病变标志物的有用性的研究应考虑先前的PRP作为影响因素。最后,我们的结果表明,严重糖尿病性视网膜病患者的视网膜来源Lam-P1强烈有助于血清Lam-P1。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号